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Phospholipase D (PLD) is a crucial signaling enzyme involved in many cellular 
processes. The catalytic activity of PLD is essential for the production of Phosphatidic Acid 
(PA), a critical second messenger in cell signaling cascades downstream. Using the highly 
invasive rat mammary adenocarcinoma cell line mTLn3 as a metastatic model, we investigated 
the proficiency of these cells to invade using matrigels that mimic the basement membrane of the 
extracellular matrix (ECM), their activity through PLD enzymatic assays, as well as the potency 
of our potential inhibitors to inhibit PLD-mediated cell invasion and lipase activity. 
This study reveals that PLD-mediated cell invasion is dependent on protein-protein 
interactions with other cell signaling molecules such as Grb2 and Rac2 and their effect on lipase 
activity. Regulation of PLD2 activity by phosphorylation on tyrosine residue sites within its 
Phox domain are examined; in which we elucidate the effects of specific kinases EGFR, Jak3 
and Src on cell invasion and enzymatic activity. Based off this approach, a therapeutic resolution 
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Cell Invasion in Metastasis 
 
 Metastasis is a multi-step model comprised of the growth of a primary tumor, 
intravasation (cell invasion), arrest and growth in a secondary site 
1
. One such example is 
breast cancer, the 2
nd
 leading cause of cancer death in Western nations ( 1
st
 among 
women), the primary cause of mortality being the metastatic spread of tumor cells from 
their primary site to other organs in the body 
2
. By limiting cell invasiveness, tumor cells 
would be unable to enter the bloodstream and extravasate to distant sites in the body, 
stopping the spread of cancer. The cell line chosen to study this metastatic model was the 
MTLn3 rat mammary adenocarcinoma, an optimal model to study breast cancer 
progression and treatment 
3
. Increased tumor cell motility and invasion is often the 
consequence of an overexpressed epidermal growth factor receptor 
4
, in which we 





















II. Literature Review 
 
The Enzymatic Role of Phospholipase D 
 
Phospholipase D (PLD) is an enzyme located within the plasma membrane that 
catalyzes the hydrolysis of phosphatidylcholine, targeting its ester linkage to yield the 
product phosphatidic acid (PA) and the release of a soluble choline headgroup. When 
water is replaced as the nucleophilic acceptor by a primary alcohol such as butanol, PLD 
can yield phosphatidylbutanol through a second reaction known as 
transphosphatidylation (Figure 1) 
5,6
. This catalytic reaction allows us to assay an indirect 
measurement of PLD activity in vitro by quantifying the amount of [
3
H]phosphatidyl-




A Brief History and Background of Phospholipase D 
 The discovery of PLD in plants came in 1947 by Hanahan and Cahikoff, who 
were the first to describe its enzymatic activity in carrots 
7,8
. In animals, PLD was found 
to suddenly activate in a direct response to extracellular stimuli 
9
. PLD is also an 
important regulator of many cellular functions through the production of second 
messengers such as PA and the products of its metabolism, diacylglycerol (DAG) and 
lysophatidic acid (LPA), all of which are involved with numerous cellular and 




Mammalian PLD Structure 
 
 There are 2 isoforms of the PLD gene, PLD1 and PLD2 (Figure 2). Park et. al 
localized each gene through in situ hybridization, PLD1 in the long arm (q) of 





Figure 1:  In the first part of the reaction, a PA-PLD intermediate is formed by a covalent 
linkage of PA to a histidine. In the second part of the reaction, two outcomes may occur. 
Hydrolysis will produce PA when H2O is present; transphosphatidylation will produce a 
























Figure 2:  The four conserved regions are indicated by roman numerals, the ‘HKD’ 
motifs responsible for catalytic activity are in yellow. PLD1 possesses a 116-residue 














. Approximately 50% amino acid homology is shared between the two 
15
. 
The PLD1 gene is a 120 kDa protein that encodes an 1074-amino acid protein; PLD2 
encodes a 933-amino acid protein with a molecular weight of 106 kDa 
9
. Four splice 
variants are yielded from PLD1 (PLD1a1, PLD1a2, PLD1b1, PLD1b2) 
16
. PLD2 yields 
two splice variants, PLD2a and PLD2b, functionally indistinguishable from the other 
17
.  
 All members of the PLD superfamily contain two highly conserved catalytic 
domains known as HKD motifs (HXKX4DX6), essential for enzymatic activity 
18
. Other 
conserved regions within the PLD family include a PI4,5P2 (PIP2) binding site, pleckstrin 
homology (PH) domain, and phox homology (PX) domain 
19,20
.  The PX domain, located 
at the N terminus, is involved in intracellular protein localization, enabling binding to 
SH2/SH3-containing tyrosine kinases 
21
. The PX domain also serves as a binding motif 
for proteins or lipids and has been shown to function as a GTPase activating protein 
22
.   
 
Tissue and Subcellular Distribution of PLD1 & PLD2 
 
Steed et. al found that human PLD1 does not
 
appear to be an abundant message in 
tissue whereas
 
levels of human PLD2 mRNA were higher and more variable 
17
. In 
cancers with elevated tyrosine kinase expression, such as breast cancer, elevated 
expression of PLD1 and elevated PLD activity was reported in breast cancer tissues 
23,24
. 
Elevated PLD activity has also been observed in gastric 
25
 and renal cancers 
26
, and a 




 Both PLD1 and PLD2 are palmitoylated on conserved Cys residues; this fatty 
acylation being a likely contributor to membrane association 
28
. PLD1 is located 





Endogenous PLD2 is evident on the plasma membrane; however, much of the enzyme is 
localized to the Golgi region and cytosolic puncta 
29
. Overexpressed PLD2 is primarily 
found on the plasma membrane, where association with ARF6 (small-GTPase that 
regulates
 
the membrane trafficking between the plasma membrane and endosome)
30
 and 
EGF receptor occurs at sites of membrane ruffling 
31
. PLD2 is also present in the cytosol 
31
, as well as a submembraneous vesicle compartment likely endocytic in origin that 




Intracellular Regulators of PLD2 
 PLD1 exhibits low basal activity that requires activation by numerous factors, 
while PLD2 exhibits high basal activity 
17
. Due to the difficulty of transfecting multiple 
PLD1 activators into the cell, we instead focus largely on PLD2 in this study.  
PLD2 is subject to complex regulation by numerous molecules such as the Rac 
and Rho-GTPase family, protein kinase C (PKC) and alternative reading frame tumor 
suppressor (ARF) 
5
. PLD2 can be modestly activated by ARF proteins 
32
. Some positive 
response from PLD2 from phorbol esters has also been observed, indicating a role for 
PKCα in PLD2 regulation 
33
. PLD2 is also activated by unsaturated fatty acids such as 
oleate, linoleate and arachidonate 
34
. Additionally, upregulation of PLD2 occurs through 
cell surface receptors when cells are stimulated by EGF or insulin, PLD2 will become 
tyrosine-phosphorylated and form a complex with the EGF receptor 
35
. PIP2 is required 
for PLD activity 
36
. Phosphoinositide regulation by PIP2 has been identified to occur 
between motifs II and IV on PLD2, a conserved region of 10-20 residues known as ‘KR’ 
motifs (18). When mutated, PIP2 dependent activation is lost 
19
. PLD2 activity is also 
 7 
regulated by phosphorylation-dephosphorylation by 3 specific kinases: EGF-R, Jak3 and 




Physiological Functions of PLD 
 
 PLD plays a role in numerous physiological and pathological processes, some of 
which include: endocytosis, exocytosis, membrane vesicle trafficking, cell migration, 
mitosis, cell survival, growth, transformation and tumor progression 
38
, actin cytoskeleton 
remodeling and stimulation of actin stress fiber formation 
31,39
, mitogenic signal 






 and leukocyte 
chemotaxis, cell polarity, adhesion and actin polymerization 
45
.  
PLD-derived PA can function as a membrane anchor that transiently targets 
specific proteins to recruit or activate PA-domain containing proteins, such as the kinase 
Raf-1 
46,47
. The list of PA binding proteins is extensive, some of which include: PI4P5K 
(generates PIP2 from PIP), mammalian target of rapamycin (mTOR), ribosomal p70 S6 
kinase (p70S6K), small GTPase Rac, kinase suppressor of Ras and the Ras guanine 
nucleotide-exchange factor Son of sevenless (Sos) 
48,49
. PIP2 synthesis by the PI4P5 
kinase, a downstream target of PLD signaling, can be stimulated by PA 
5
, because PLD is 
activated by PIP2, this interaction may represent a positive feedback loop that activates 
PLD2 in lipid rafts 
38
. PA will also function in cellular signaling pathways as a direct 
lipid second messenger or as an indirect precursor, once converted to other bioactive 
lipids such as LPA and DAG 
9-11
. Generation of PA engineers the recruitment of Raf to 
the plasma membrane, resulting in activation of the mitogen-activated protein kinase 
(MAPK) pathway 
38,46,47
. PA is also required for activation of mTORC1 in mTOR, the 
 8 
protein kinase that regulates both cell cycle progression and cell growth 
50
, both 
downstream targets of PLD implicated in cell survival. A downstream target of mTOR, 
p70S6K, is phosphorylated, catalyzing the phosphorylation of the S6 protein to initiate 
protein synthesis 
51,52
. PA also activates S6K independently of mTOR 
53
. Not only does 
PLD enhance cell proliferation and survival, it can also prevent cell cycle arrest 
54
 and 





Grb2 and its Interaction with PLD2 
  
 Growth receptor bound protein 2 (Grb2) is a 25 kDa adapter protein comprised of 
one SH2 domain and two SH3 domains responsible for signal transduction between 
growth factor receptors and intracellular signaling cascades 
56
. Grb2 is essential in 
cellular proliferation 
57,58
 and PLD2 lipase activity, intracellular localization and 
signaling in response to EGF 
59
. In colorectal carcinoma, Grb2 expression and genes 
involved in Grb2-mediated pathways were highly elevated in the metastases due to its 
role in tumor growth, invasiveness and metastasis 
60
. Cytoplasmic Grb2 relocates to the 
plasma membrane when stimulated by EGF and binds to the EGF receptor through 
phosphotyrosine containing proteins located on its SH2 domain 
61
. The Grb2 SH2 
domain, in addition, serves for recruitment to the phosphotyrosine motif p-YxN located on 
the PH domain of PLD2 
62
. The two SH3 domains of Grb2 interact with proline-rich 
motifs of signaling proteins, the most important being Sos 
63
. The Grb2/Sos complex can 
form independently of PLD2 and has been associated with embryogenesis, regulation of 
the cytoskeleton, DNA synthesis and cancer 
57,61,64
. Once the Grb2/Sos complex is 
formed, mitogenic Ras effectors are activated, stimulating cellular proliferation and the 
 9 
MAPK cascade downstream 
63
. PLD2 binds Grb2 and recruits Sos, while PLD-derived 
PA can bind Sos directly, both interactions are able to promote GTP loading of Ras and 
the stimulation of the MEK/ERK pathways 
65




 are a 
necessary requirement to directly bind Grb2 and recruit Sos in vivo, Y
169
 modulates 
activity of the enzyme while Y
179
 regulates tyrosine phosphorylation of the protein 
21
. In 
addition to these sites, Y
511
 has also been shown as a tyrosine interaction site between 






 are phosphorylated, PLD2/Grb2 mediates lipase 
activity, when dephosphorylated, lipase activity decreases and mediates an induction of 





Rac2, CRIB, and their Interaction with PLD2 
 
 Rac2 is a GTPase belonging to the Ras superfamily of small GTP-binding 
proteins, involved in cell spreading, migration, mitogenesis, actin cytoskeletal 
rearrangement, phagocytosis, superoxide generation and axonal growth 
67
. Innate immune 
responses depend upon neutrophil movement and phagoctyic leukocytes to respond to 
invading pathogens 
68
. The first human disease discovered due to a mutation of a Rho 
GTPase was human neutrophil deficiency syndrome, due to an inhibitory Rac2 mutation, 
as Rac2 is a critical regulator of chemotaxis 
68,69
. Rac2 is involved in regulation of 
hematopoietic stem cells (HSC), actin polymerization, adhesion and migration, phagocyte 
NADPH oxidase, and along with Rac1, the ability to individually control HSC cell cycle 
progression and survival 
70,71
. Rho GTPases have a significant role in the development of 
cancer; these roles include cell transformation, proliferation, invasion, metastasis, and 
 10 
angiogenesis, with recent research showing a remarkable increase of Rac2 expression in 
head and neck carcinoma 
72,73
.  
 Peng et. al has demonstrated for the first time that upon cell stimulation, PLD2 
translocates from the nucleus and golgi region to the cell membrane where it interacts 
with Rac2 (unpublished results). Rac2 binds to the PH domain of PLD2 at a newly-
identified Cdc42/Rac Interactive Binding (CRIB) domain and affects lipase activity. The 
protein interaction between PLD2 and Rac2 are shown in Figure 3.  
A Rac2-PLD2 interaction could exist and serve to modulate PLD enzyme activity, 
perhaps leading to an enhanced functionality where both molecules have been implicated. 
When EGF is present, Henkels et. al have shown that Rac2 protein expression increases 
substantially when co-transfected with PLD2 (Figure 4). This increase in Rac2 protein 
expression indicates that PLD2, when stimulated by EGF, upregulates Rac2 protein 
expression. 
 
MTLn3 Cell Line 
 
 MTLn3 cells are a highly invasive and metastatic rat mammary adenocarcinoma, 
a widely used model to observe metastases. MTLn3 cells overexpress EGF receptors 
(EGFR), roughly 50,000 per cell, affecting a multitude of different signaling pathways 
74
. 
EGFR, a member of the ErbB/HER tyrosine kinase receptor family, can undergo 
mutations in disease to become constitutively active, the dysregulation of which leads to 
tumor progression, angiogenesis and metastasis 
75
. Binding of EGF to its receptor induces 
receptor dimerization, phosphorylation of specific tyrosine residues recruit cytoplasmic 




Figure 3:  HA-tagged PLD2 and myc-tagged Rac2 were overexpressed in COS-7 cells. 
By pulling down with immunoprecipitation (IP) and probing for their tags in a Western 
Blot, we observe the necessity of the CRIB domain for Rac2 binding. In both parts, PLD2 
and Rac2 protein are shown. In part A, when DCRIB (deletion of CRIB domain) is 
overexpressed, Rac2 protein pulldown decreases significantly from the PLD2 + Rac2 co-
transfection. Part B examines CRIB2, in which the deletion of that domain again 
significantly decreases Rac2 protein pulldown, indicating that Rac2 protein expression is 






Figure 4:  Similar to Figure 3, Rac2 and PLD2 protein interaction is examined in COS-7 
cells. Part A illustrates the tags overexpressed by PLD2 and Rac2. Part B, shows that 
when EGF is not present, Rac2 protein can barely be pulled down. In contrast, EGF-
stimulated Rac2, when interacting with PLD2, is pulled down at a much higher level. 
Therefore, there is an EGF-mediated interaction between PLD2 and Rac2 protein 
expression. 
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phosphatidylinositol 3-kinase (PI3K) and signal transducers and activators of 
transcription (STAT), all critical players in cancer progression 
75-78
.  
 MTLn3s are an estrogen receptor (ER) positive cell line. ER are overexpressed in 
70% of breast cancers, known as ER+; binding of estrogen to the ER stimulates cell 
proliferation and an increase in cell division and replication 
79,80
. Though we know EGFR 
overexpression and ER exposure are critical in the pathogenesis of cancer, anti-estrogen 
drug therapies targeting cell proliferation has shown limited efficacy in deterring  
tumor progression 
4
. MTLn3 as a metastatic cancer is highly prevalent due to its invasive 
capabilities, which provide another possible mechanism to target other than proliferation. 
One reason why these cells are so invasive is due in large part to their ability to undergo 
epithelial mesenchymal transition, in which morphological changes, cytoskeletal 
restructuring and intracellular E-cadherin redistribution contribute to intravasation 
81
. Cell 
growth and their metabolic processes are heavily influenced by cell shape and cell-cell 
adhesion/spreading 
82
. The maintenance of these cell-cell interactions involve tight 
cadherin based junctions and cell polarity 
81
. Mesenchymal cells dysregulate these 
interactions and allow invading cells through the ECM through atypical cell surfaces that 
result in the loss of cell polarity and the synthesis and organization of matrix degrading 
metalloproteinases (MMPs) 
81
. MTLn3 cells in particular have been shown to have high 
levels of cadherin and proteases (regulators of cell-cell adhesion), low levels of TIMPs 
(inhibitors of MMPs), loss of intrinsic cell polarity, overexpression of apoptosis 
supressors and the dramatic polarization of these cells that allow for chemotaxis toward 
the blood vessels in MTLn3 tumors 
83
. The ability for chemotaxis in this 
microenvironment is due to  EGFR signaling from the blood vessels, which involves 
 14 
small GTPases of the Rho family, enhancing metastatic capablities in addition to the well 







 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI) is a pharmalogical inhibitor of 
PLD that is able to potently and efficiently block in vivo PA production by inhibiting the 
catalytic activity of PLD 
84
. In addition, FIPI inhibits PLD regulation of cell spreading, 
chemotaxis, F-actin cytoskeletal reorganization without delocalization of proteins (such 
as sequestering PIP2) or any identifiable effects on other pathways independent of PLD 
84
.  
 The flavonoid apigenin (4,5,7-trihydroxyflavone) (Api), is a nonmutagenic 
bioflavonoid from leafy plants and vegetables that exhibit many different anti-
inflammatory, antioxidant and anti-carcinogenic properties, emerging as one of the more 
promising cancer chemopreventive agents being studied today 
85
. Apigenin has been 
reported to inhibit PKC and MAPK activity 
86,87
, extracellular signal regulated kinase 
(ERK) 
88
, and the decrease of phosphorylated EGFR tyrosine kinase 
89
. Dr. Cambronero’s 
lab has proposed that Api may inhibit PLD enzymatic activity and affect PLD2/Rac2 
binding due to observed decreases in lipase activity and the increase Rac2 exerts onto it 













The objective of the present study is to investigate if PLD2 is mediating cell 
invasion in mTLn3 cells and the hypothesis is that the mechanism of PLD2-mediated cell 
invasion either involves protein-protein interaction with other cell signaling molecules, 
such as Grb2 and Rac2, a dependence on lipase activity, or both.  
Specific Aims 
 
 In order to test this hypothesis, we outlined a series of experiments within our 
four Specific Aims: 
AIM 1:  How does modulation of PLD activity affect invasion? We assayed MTLn3 
cells for cell invasion in Matrigel by EGF stimulation over a period of 20 hours. Cell 
invasion was preceded by transfecting siRNA PLD (for loss of function), as well as 
overexpressing the Wild-Type (WT) PLD plasmid (for gain of function) and the lipase 
dead KR mutants before the cells underwent invasion. We also introduced the 5 potential 
inhibitors to examine their effect on PLD in cell invasion and their effect on PLD 
enzymatic activity.  
AIM 2:  To investigate if there is an effect of Grb2 on PLD2-mediated cell invasion 
and lipase activity. To determine the effect of Grb2 on PLD, we silenced endogenous 
Grb2WT; we also overexpressed Grb2 WT and the mutants (R86K SH2-deficient and 
p49/206L SH3-deficient), as well as PLD2 YF (Tyr residue substitutions) mutants 
(Y169F, Y179F, and Y511F) and followed cell invasion. We examined these plasmid 
constructs additionally through co-transfections with PLD, enzymatic assays and the 
effect of the 5 potential inhibitors.  
 16 
AIM 3:  To investigate if there is an effect of Rac2 and CRIB on PLD2-mediated cell 
invasion and lipase activity. This set of experimental procedures followed the same 
outline as our Grb2 plasmids. By transfecting our Rac2WT and Rac2 N17 (GDP-bound) 
plasmids, we were able to investigate their effects on invasion and activity. We also 
elucidated the role of the PLD-Rac2 interaction in the mTLn3 cancer cell line. 
Introduction of the PLD2 CRIB domain mutations (in the PH domain), ∆CRIB1 and 
∆CRIB2, further defined this interaction.  
AIM 4:  To investigate the effect of kinase phosphorylation of PLD2 on PLD2-
mediated cell invasion and lipase activity. Specific tyrosine residue sites on PLD2 were 
examined in this study, as kinase activity is known to affect lipase activity of PLD2. 
Within this aim, we studied the PLD2 YF mutants 296, 415, and 511 that disable kinase 













IV. MATERIALS AND METHODS 
Materials 
 The rat mammary adenocarcinoma cell line mTLn3 was a gift from Dr. Jeffrey D. 
Segall (Albert Einstein College of Medicine). MTLn3 culture medium α-MEM, 
Lipofectamine 2000, Opti-MEM, Trypan Blue and EGF were all obtained from 
Invitrogen (Carslbad, CA). The matrigel inserts were purchased from BD (Franklin 
Lakes, NJ). Hematoxylin stain was obtained from Ricca (Arlington, TX). For silencing, 
pre-designed siRNA for PLD1 targeting exon 10 and siRNA for PLD2 targeting exon 15 
and exon 6-9 were purchased from Ambion (Austin, TX). The siRNA of Grb2 and Rac2 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). siQuest was 
purchased from Mirus (Madison, WI). Negative control siRNA was purchased from 
Ambion (Austin, TX). ECL reagents used for western blotting were purchased from GE 
Healthcare (Piscataway, NJ). Maxi-prep plasmid kits were purchased from Qiagen 
(Valencia, CA). Restriction enzymes were purchased from New England BioLabs 
(Beverley, MA).  
Methods 
Cell Culture and Plasmid Transfections.  
MTLn3 cells were cultured in α-MEM plus 5% FBS, 50 U/mL Penicillin, 50 
µg/mL Streptomycin and 50 µg/mL Gentamycin. Cells were split at 60% confluency. The 
cells were transfected at 50% confluency per well with plasmids ranging from 1-6 µg of 
DNA, using 2 µl Lipofectamine 2000 per µg of DNA diluted in Opti-MEM. Sterile glass 
culture tubes housed each lipid-DNA complex prior to pipetting the solution into 6-well 
plates of cells containing 2 mL of α-MEM plus 5% FBS only per well. The cells were 
 18 
then incubated overnight at 37˚ C in a humidified 5% CO2 atmosphere and the following 
morning media replaced with fresh complete α-MEM.  
 
Gene Silencing.  
For PLD silencing, a negative control and three pre-designed siRNAs were used. 
PLD1 siRNA targeting exon 10 and PLD2 siRNA targeting exon 15 and exon 6-9. The 
silencing of Grb2 and Rac2 were also performed (Table 1). The siRNA was transfected 
by diluting the siRNA in Opti-MEM, followed by the addition of siQuest. Each reaction 
was incubated for 20 minutes at room temperature before being pipetted dropwise onto 
the cells. Cells were incubated at 37˚ C in a humidified 5% CO2 atmosphere and media 
was replaced after 24 hours. Silencing occurred for 4 days prior to assay. 
 
Cell Invasion.  
Cells were serum starved for 2 hours in α-MEM medium supplemented with 12 
mM HEPES (MEMH) and 0.1% BSA. This same buffer was used to pre-wet the matrigel 
inserts (8 micron pores) prior to assaying. The cells were then harvested by disassociating 
with 3 mM EDTA/PBS, sedimented and counted using Trypan-Blue. Cell viability was 
uniformly > 95%. 1x10
5
 cells were then loaded into the top of the insert, while the 
bottom wells contained EGF. The inserts were then incubated for a period of 20 hours 
and fixed in 10% paraformaldehyde for 15 minutes, followed by staining in hematoxylin 
for 2 hours. 6 fields within the inserts were then counted by inverted microscopy at 20x 
magnification and multiplied by a factor of 45 to account for the area of the insert. These 
























Table 1:   







error bars are a standard error of the mean, which take into account the differences 
between cells per field. Inhibition of cell invasion was performed by resuspending the 5 
inhibitors in DMSO at 6-10x their IC50 concentrations. The inhibitors were present in the 
bottom well with the culture media that contains chemoattractant.  
 
PLD Enzyme Activity 
 Measurement of lipase activity began with the addition of the following reagents: 
3.5 mM PC8 phospholipid, 45 mM HEPES at a pH of 7.8 and 1µCi of n-[
3
H] butanol. 
Samples were incubated for 20 min at 30˚ C with continuous shaking. The reactions were 
then stopped with 300 µl of ice-cold chloroform/methanol (1:2). The lipid layer was then 
isolated and resolved by thin layer chromatography for 50 minutes. The lipids bound to 
the plate were visualized with iodine vapors. The amount of [
3
H] PtdBut that co-migrated 
along with the PtdBut standards was scraped and quantified by scintillation spectrometry. 
The control reactions contained no PC8, removing background counts. Inhibition of 
enzyme activity was similar to cell invasion, except the cells were incubated with the 
inhibitors for 20 minutes in a reciprocal shaking bath prior to assay. 
 
Immunoprecipitation and Western Blotting 
 After cells were collected, they were then lysed in Special Lysis Buffer (50 mM 
HEPES, pH 7.2, 100 µM NA3VO4, 0.1% Triton X-100 and 5 mg/ml each of aprotinin and 
leupeptin) and sonicated. BIO-RAD protein assays were utilized to determine protein 
concentration and normalize for protein per reaction. The samples were then conjugated 
with anti-myc agarose beads overnight. Immune complex beads were then sedimented, 
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washed with buffer A (100 mM Tris-HCl, pH 7.4, 400 mM LiCl) then buffer B (10 mM 
Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA). The beads were resuspended in a final 
volume of 60 µL 4x SDS running buffer for subsequent gel electrophoresis. These gels 
were then transferred for 1 hour onto PVDF membrane, blocked for 2 hours at room 
temperature with 2.5% BSA with TBS, 0.2% Tween 20 and probed with primary 
antibody overnight. Secondary antibodies conjugated to horseradish peroxidase were 
detected on x-ray films with the use of ECL reagents. The Kodal Gel Logic software used 
to perform densitometry on Western Blot samples which consists of quantifying the band 
of the protein of interest versus the band of the actin control.  
 
Maxiprep for DNA Constructs and Restriction Enzyme Digestion 
 E. coli colonies were grown in LB broth media and processed through the Qiagen 
maxiprep kit. Once the plasmids were extracted, the concentration and purity were 
determined by spectrophotometry at OD260/280. The plasmids were then verified by 
restriction enzyme digestion using 0.4% agarose with ethidium bromide. Gels were 










AIM 1:  Is PLD causing invasion in mTLn3 cells? 
A.  Roadmap of Proteins and Protein Interactions 
 In Figure 5, we outline the roadmap of this thesis with the proteins involved in 
this study and their interactions with each other. In Aim 1, we looked exclusively at the 
effects of PLD1 and PLD2 on cell invasion and enzyme activity, as well as the 
effectiveness of the 5 potential inhibitors in targeting and affecting the functions of these 
proteins. 
 
B. Overexpressing Plasmid DNA for Cell Invasion in Matrigels 
 Initially, we observed the effect of overexpressed WT and mutant PLD plasmids 
on cell invasion in order to gauge their relative effects. As is the case for every one of the 
cell invasion assays, we run a mock, unstimulated sample and conversely a mock sample 
stimulated with EGF. In this particular experiment, we included transfections of our PLD 
WTs and lipase dead KR mutants with and without chemoattractant. Relatively similar to 
silencing, the KR mutants deprive PLD of its lipase activity. Without an active lipase, 
dominant negative cell signaling is interrupted. The results of this initial invasion assay 
are right in line with what we expected. Our PLD1 and PLD2 WT plasmids, even without 
EGF stimulation surpass the EGF control (Figure 6a). With chemoattractant, we see a 
considerable enhancement in invasion with PLD2 WT. PLD1 and PLD2 KR mutant 
plasmids were utilized and both decreased invasion. In each cell invasion assay presented 






Figure 5:   
This roadmap covers the 4 major proteins of study (PLD1, PLD2, Grb2, Rac2) and 
illustrates the interactions between them. In AIM 1 we examined PLD1 and PLD2 
exclusively. The WT or mutant DNA constructed to study that particular protein of 
interest is linked nearby. In the case of certain plasmids, their effects expand beyond only 
1 protein of interest. One such example is the tyrosine residue site Y169 where PLD2 






            
 
Figure 6:   
Part A illustrates the increase in invasion with PLD WT present within the cell, and the 
subsequent loss of invasion when the lipase dead KR mutants are overexpressed. Part B 
verifies our overexpression of PLD1 and PLD2 by probing for their tags, HA and myc, 
respectively. Actin is probed as a loading control.  
 25 
decreases (#) from the control. In Figure 6a, the p value of PLD2 WT compared to the 
EGF control is 0.001, any p value less than 0.05 (within 95%), is statistically significant. 
 
C.  Silencing Gene Expression. 
 To verify PLD as essential for cell invasion in MTLn3 cells, we knocked down 
PLD2 with siRNA before assaying for cell invasion. In order to investigate and verify the 
loss of gene expression and its effects, we silenced PLD2 in a dose response fashion from 
0 nM to 200 nM of siRNA (Figure 7a). We observed subsequent loss of protein 
expression correlated with the amount of siRNA transfected, indicating a loss of PLD2 
expression in our protein samples. Additionally, Figure 7b depicts the densitometry of 
PLD2 silencing in relation to actin staining as shown in our western blot. Again, we see a 
consistent loss of protein (up to 90% expression decrease with the highest concentration 
of siRNA) expressed with increasing amounts of siRNA. The effectiveness of PLD1 
silencing was difficult to perform and interpret (data not shown). Now that the efficacy of 
the PLD2 siRNA has been established, we investigated its effect on cell invasion. If 
PLD2 is truly essential to invasion, then we expect to see a significant decrease in the 
ability of MTLn3s to invade through the basement membrane of our matrigel inserts 
following PLD2 silencing. Accordingly, we observed an 85% decrease in EGF-mediated 
cell invasion when PLD2 was silenced, confirming the requirement of PLD2s role in cell 
invasion (Figure 8).  
 
D. Effect of Inhibitors on PLD Mediated Cell Invasion 









A.      B. 




Figure 7:   
In Parts A-B we show two different data sets on the effectiveness of PLD2 siRNA. Part A 









Figure 8:   
This graph shows that in the presence of the EGF, PLD2 is crucial for invasion. 
Compared to the mock, the amount of cells invading drops roughly ~85% when PLD2 is 
not being expressed. 200 nM siPLD2 exon 15 was used prior in this study, however 
siPLD2 exon 6-9 was also utilized in this assay to verify that the silencing of PLD2 could 
also occur by suppressing another part of the gene. This assay also shows that a negative 
control (a mock transfected condition with siRNA that does not target any particular gene 
sequence) had a neutral affect on cell invasion. This control eliminates possible 




the MTLn3 cell line. First, we performed a dose response cell invasion assay of the 
inhibitors in MTLn3s with (Figure 9) or without chemoattractant (data not shown). Our 
goal was to determine IC substrate 50 (IC50) concentrations for each compound. These 
compounds were inhibitory and largely effective at subnanomolar doses (Table 2). Once 
we established our IC50 for each inhibitor, we investigated their effects on overexpressed 
PLD1 WT and PLD2 WT (Figure 10). All the compounds excluding FIPI slightly 
inhibited PLD1-mediated cell invasion with compound APV eliciting the greatest 
decrease. PLD2-mediated cell invasion on the other hand was more significantly 
decreased in the presence of all 5 compounds. Api, 5WO, 809, APV and FIPI all 
inhibited PLD2 mediated invasion approximately 50%. This confirms that the invasive 
capability of MTLn3 cells overexpressing PLD2 WT can be decreased significantly when 
exposed to these inhibitors in vitro. In this case, PLD2 was targeted and knocked down 
much more effectively than PLD1. 
 
E. Effect of Inhibitors on PLD Enzymatic Activity 
 The 5 inhibitors, to be truly effective, must possess the ability to inactivate PLD 
catalysis. If the effects of cell invasion are consistent with the effects on activity, then it is 
likely only the PLD pathway is being affected. An enzymatic assay of PLD was 
performed with the same conditions used for cell invasion. (Figure 11). Insignificant 
inhibition of PLD1 activity occurred in the presence of the 5 inhibitors. However, in the 
case of PLD2, lipase activity was decreased 30% in the presence of Api, 809, or APV, 





Figure 9:   
The effect of the 5 potential inhibitors on cell invasion in the presence of EGF is shown 
here. These plots were used to determine IC50 concentrations for optimal utilization in 
cell invasion inhibitor assays. Each IC50 concentration was determined from the graphs at 
the midpoint of optimal inhibition, the working concentration used in each inhibitor assay 
is 6-10x that amount. The cells can still migrate with higher doses of inhibitor present, 





IC50 Concentrations of the 5 Potential Inhibitors 
Cell Invasion Assay Values: 
Compound        IC50 (nM)          Working Concentration (nM) 
Apigenin 5 30 
5WO 4.5 30  
809 6.5 100  
APV 30 300 
FIPI 4.5 30  
 
 
Table 2:   
The MTLn3 cell line underwent a dose response cell invasion assay with increasing 
amounts of inhibitors. ICsubstrate50 (half maximal inhibitory concentration) is the 
functional strength of the inhibitor, measuring the effectiveness of the compounds to 








Figure 10:   
The effect of the inhibitors on PLD mediated cell invasion. PLD1 is relatively unaffected 
while PLD2 exhibits ~50% inhibition. There is also a control DMSO group to account for 
its effect (all inhibitors are resuspended in DMSO), which is run in every assay involving 
the inhibitors. When PLD is not overexpressed, untransfected cells are inhibited similar 
to the IC50 graphs, but significantly less that that of overexpressed PLD2 WT (data not 






Figure 11:   
Each enzyme assay presented is in DPM/µg, disintegrations per minute corrected for total 
protein. This PLD enzymatic activity assay shows a direct effect on the catalytic activity 
of PLD2 by the 5 inhibitors. Similar to the effects seen in cell invasion, PLD2 
experiences ~50% inhibition. PLD1 is unaffected. Only with FIPI do we begin to see an 
affect, and in the case of apigenin, we actually see a small spike in activity. We repeated 
additional independent experiments with the inhibitors on PLD WT and observed a 




AIM 2:  Investigate if there is an effect of Grb2 on PLD2-mediated cell invasion and 
lipase activity. 
A.  Roadmap of Proteins and Protein Interactions 
In the second aim, we investigated the protein-protein interaction between Grb2 
and PLD2 on cell invasion and enzymatic activity. We also investigated the effect of 
inhibitors on the PLD2-Grb2 association (Figure 12).  
  
B.  Overexpressing Plasmid DNA for Cell Invasion in Matrigels 
 Our next step was to observe the overexpressed plasmids of Grb2 and their effects 
on cell invasion. In addition to our Grb2 WT, we used the SH2-domain deficient R86K 
mutant, as well as the SH3 domain-deficient double mutant p49/206L. Assaying these 
plasmids in cell invasion, we were able to observe the effect Grb2 has on PLD2-mediated 
cell invasion (Figure 13).  
 
C.  Overexpressing PLD2-Grb2 YF mutants in Cell Invasion 






.  The YF 
mutants at these sites render PLD2 incapable of binding Grb2. Figure 14a is the 3 YF 
mutants overexpressed in a Western Blot and Figure 14b the result of cell invasion. As 
expected, the loss of PLD2’s ability to bind to Grb2 results in significant decreases in cell 
invasion.  
 
D.  Silencing Gene Expression. 






Figure 12:   
The next area of study within the roadmap is the effect of Grb2 on PLD2 mediated cell 
invasion and lipase activity. The specific tyrosine residue sites for protein-protein 
interaction between these two proteins are Y169, Y179 and Y511 on PLD2 (indicated by 
the green lines). Grb2WT, Grb2 mutants and PLD2 YF mutants will be used to determine 
the role of Grb2 in cell invasion (dotted lines). The inhibitors effect on Grb2 and its 





Figure 13:   
Grb2 WT increases invasion above the EGF control, though its effects are not as strong 
as PLD2WT. The Grb2 R86K mutant shows no effect. The double Grb2 mutant 
p49/206L has a negative effect on cell invasion. The Grb2WT + PLD2 WT co-
transfection enhances cell invasion, while our Grb2 R86K + PLD2WT co-transfection 
shows no increase from that of the PLD2 WT control sample. The addition of PLD2WT 
to Grb2 p49/206L does not change the negative effect of this Grb2 mutant on cell 
invasion. 
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Figure 14:   
Part A is a Western Blot of the overexpressed mutants, which were also probed for 
endogenous PLD to verify overexpression. Part B illustrates the decrease in cell invasion 
by preventing PLD2 binding to Grb2 when the YF mutants are overexpressed . (Y165F 
data not shown, Y296F data presented later) 
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performed a dose response of siGrb2 RNA in the same manner as for PLD (Figure 15a). 
Additionally, we also quantified the silencing using densitometry (Figure 15b). The 
siRNA proved to be effective, knocking down Grb2 protein expression levels by over 
90% in relation to increasing levels of siRNA.  By successfully knocking down Grb2, we 
can determine the importance of the role it plays on PLD2 in mediating cell invasion. We 
silenced Grb2 alone or in combination with PLD2 silencing and then assayed for cell 
invasion (Figure 16). The results are clear that silencing Grb2 only negatively affects the 
ability of MTLn3 cells to invade. siPLD2 alone has a greater negative effect than siGrb2 
alone. Because of the importance of the PLD2-Grb2 interaction, simultaneously knocking 
down the gene expression of both PLD2 and Grb2 lowers the cell invasion to less than 
basal levels.   
 
E.  Silencing and Rescuing Protein Expression 
 
To examine this interaction further, we immunoprecipitated (IP) Grb2, PLD2 and 
co-transfected PLD2-Grb2 samples by pulling down PLD2 with α-myc agarose beads and 
performing a Western Blot to probe for interaction with Grb2 and determine protein 
expression. By silencing PLD2 first and then overexpressing the same conditions to 
observe the effect siPLD2 had on Grb2, protein expression is similar in both the Grb2 
WT only and PLD2 WT + Grb2 WT co-transfection (Figure 17). PLD2 does not control 
the gene expression of Grb2; the effects of this interaction are likely further downstream.  
 
F.  Effect of Inhibitors on Grb2’s Role in PLD Mediated Cell Invasion 







A.        B. 
                   
 
 
Figure 15:   
Part A shows the decrease in protein expression of siGrb2 in a Western Blot. Part B is the 
densitometry measured from the same blot. A substantial decrease in the Grb2 protein 













Figure 16:   
This silencing invasion assay illustrates the negative effects on invasion when silencing 
Grb2 or PLD2 alone and most effectively the PLD2 + Grb2 co-silencing. When neither of 










      
                                     
 
 
Figure 17:  
Grb2 WT and PLD2 WT were overexpressed and immunoprecipitated. PLD2 was 
silenced prior to transfection for protein overexpression. The similarity in protein 
expression between Grb2 WT only and PLD2 WT + Grb2 WT indicate PLD2 has no 








investigated the extent to which the inhibitors would knock it down. We also did this with 
the Grb2WT + PLD2 WT co-transfection, a strong performer in cell invasion (Figure 18). 
We see roughly a 60% inhibition with Api, 5WO, 809 and APV on our 3 transfection 
sets. FIPI inhibits the PLD2 + Grb2 combination by ~70%, the first sign of FIPI being the 
strongest inhibitor. Some of this effect might be attributed to less PLD2 WT 
overexpressed in the co-transfected sample. 
AIM 3:  To investigate if there is an effect of Rac2 and CRIB on PLD2 mediated cell 
invasion and lipase activity. 
 
A.  Roadmap of Proteins and Protein Interactions 
In the third aim, we investigated the protein-protein interaction between Rac2 and 
PLD2 and its effect on cell invasion and enzymatic activity. We also examined the effect 
of the inhibitors on the Rac2-PLD2 association, as well as the effect the CRIB domain 
has on this protein-protein interaction (Figure 19). 
 
B. Overexpressing Plasmid DNA for Cell Invasion in Matrigels 
  
Figure 20a depicts overexpressed Rac2WT in a Western Blot. To determine the 
role of Rac2 in cell invasion, we utilized both the Rac2 WT and Rac2 N17 mutant to 
investigate the effect of Rac2 GTPase activity on cell invasion (Figure 20b). This assay 
clearly showed that GDP-bound Rac2 N17 has a positive effect on cell invasion above 
both the mock sample and Rac2WT. We discovered that GTP-bound Rac2WT has a 
neutral to slightly negative effect on cell invasion. Rac2 N17 is a better performer in cell 
invasion as GDP-bound Rac2 does not compete with the binding of PLD2 to PIP2 on the 




Figure 18:   
For cell invasion assays using the inhibitors to determine the protein-protein interaction 
between PLD2 and Grb2, we use PLD2WT as a positive control. We see ~60% inhibition 
with Api, 5WO, 809 and APV. Fipi inhibits the PLD2 + Grb2 co-transfection by ~70%. 
This is the first sign of FIPI as the strongest inhibitor, likely due to its ability to inhibit 











Figure 19:  
To determine the role of Rac2-mediated cell invasion and lipase activity we investigated 
the mutant Rac2 N17, the effect of Rac2 WT and its interaction with PLD2, as well as the 









    
Figure 20:  
 Part A is a Western Blot of overexpressed Rac2 WT. Part B is the cell invasion data 
depicting the slightly negative effect of Rac2WT and the positive effect of the mutant 





The next step was to elucidate Rac2’s interaction with PLD2 in a sequentially transfected 
cell invasion assay (Figure 21). Co-transfecting PLD2WT + Rac2WT simultaneously 
resulted in a slight decrease in cell invasion below the positive PLD2 WT control. 
Subsequent transfections of PLD2WT + Rac2WT were performed in sequence and not 
simultaneously and for differing periods of time. Regardless of the time frame used 
during sequential transfection, PLD2WT transfection before Rac2WT transfection 
resulted in an increase in cell invasion.  
 
C. Rac2-Mediated Cell Invasion and PLD Enzyme Activity  
 
To further determine the effect of Rac2 on PLD2-mediated cell invasion, we 
performed a cell invasion assay (Figure 22a) and a PLD enzymatic assay (Figure 22b) of 
simultaneously co-transfected samples. Both assays were transfected with the same 
conditions, increasing amounts of Rac2 WT in the absence or presence of co-transfected 
PLD2 WT. In cell invasion, the negative effect of Rac2 is descending in effect with 
concomitant increasing amounts of Rac. When Rac2 WT is co-transfected with PLD2 
WT, this interaction results in a more pronounced negative effect on cell invasion when 
compared to Rac2 only samples, indicating MTLn3 cells become less invasive when 
more Rac2 WT is present. The effect of Rac2 on PLD2 lipase activity further confirmed 
this negative interaction. When Rac2 WT was co-transfected with PLD2 WT, the 
catalytic activity of PLD2 decreased substantially. This pattern confirms that the negative 
effect of Rac2 on cell invasion is due to the inhibition of both endogenous and 
overexpressed PLD2 enzymatic activity. As Rac2 levels increase within the cell, PLD2 





Figure 21:   
The simultaneous transfection of PLD2 WT + Rac2 WT is the last bar in red in the 
middle of the graph and results in a slight decrease in cell invasion when compared to 
PLD2 WT alone. Additionally, this negative effect on cell invasion is also seen in the 
sequentially transfected samples when Rac2 WT is transfected before PLD2 WT. When 
PLD2 WT is transfected before Rac2 WT, the inverse effect is observed and invasion 
significantly increases above the EGF control.  
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Figure 22:   
Part A depicts the decrease in cell invasion when Rac2 WT is co-transfected with PLD2 
WT. This effect from Rac2 on PLD2 is confirmed in our enzyme activity assay (Part B). 
The black bars on the left show the negative to neutral effect of Rac2 on endogenous 
PLD activity. Recombinant PLD2 enzyme activity is decreased to endogenous levels 
when interacting with Rac2 WT, overcoming the highly catalytic overexpressed PLD2 
WT. 
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D.  Silencing Gene Expression. 
 
We verified siRac2 in a dose response Western Blot (Figure 23a), as well as 
quantifying the protein expression using densitometry (23b). As before, our protein 
expression decreased in proportion to increasing amount of siRNA.  
 
E. Silencing and Rescuing Invasion   
We performed a silence and rescue cell invasion assay involving siRac2 and 
siPLD2 in an effort to define a role for Rac2-mediated cell invasion (Figure 24). In the 
presence of chemoattractant, the result of silencing PLD2 was a 70% decrease in cell 
invasion, reinforcing the significance of PLD2 in cell invasion. siRac2 decreased cell 
invasion by 30%, indicating a role for Rac2 independent of PLD2 in mediating cell 
invasion. With no EGF stimulation to the cells, the effects of silencing Rac2 plus PLD2 
overexpression were more negatively pronounced than silencing of Rac2 alone. 
Overexpressed PLD2WT was able to rescue EGF-stimulated cell invasion after silencing 
Rac2. EGF-dependent cell invasion increased 2-fold compared to siRac2 alone. This 
increase in cell invasion indicates a possible PLD2/Rac2 interaction mediated through 
EGF stimulation.  
To determine if the gene expression of PLD2 affects protein expression of Rac2, 
we examined the effect of silencing PLD2 and subsequently overexpressing PLD2, Rac2 
and PLD2 + Rac2 by performing an immunoprecipitation and probing for Rac2 (Figure 
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Figure 23:   
Part A illustrates the decrease in Rac2 protein expression following silencing in a 
Western Blot. Part B is the densitometry measured from the same blot. Both data sets 









    
 
Figure 24:   
This silencing cell invasion assay depicted roles for both PLD2 and Rac2-mediated cell 
invasion in the presence of EGF. Silencing PLD2 resulted in a 70% decrease of cell 
invasion, while silencing Rac2 resulted in almost a 30% decrease in cell invasion, despite 
its negative interactions, possibly due to cell invasion functions independent of PLD2. 
Overexpressing PLD2WT was able to rescue siRac2 and increase cell invasion. With no 
chemoattractant stimulation, the silenced Rac2 co-transfected with PLD2WT exhibited a 
decrease in cell invasion by 70%, indicating a possible EGF-mediated interaction 
between the two proteins, based off the EGF stimulated Rac2 figure shown previously in 




              
 
 
Figure 25:   
This IP illustrates the suppression of Rac2 protein expression when PLD2WT is 
overexpressed. The negative effect of Rac2 on PLD2 may be attributed to protein 
expression, when PLD2 is silenced Rac2 WT is strongly overexpressed. When PLD2 WT 
is overexpressed to overcome the siPLD2, Rac2 protein expression diminishes, possibly 
due to the competitive nature between these two proteins. For PLD2 to mediate cell 






F. Effect of Inhibitors on Rac2-Mediated Cell Invasion and PLD Enzyme Activity 
 
To determine the effect of the 5 inhibitors on Rac2-mediated cell invasion and 
endogenous PLD lipase activity, we performed a cell invasion assay with PLD2 WT, 
Rac2 WT and PLD2 WT + Rac2 WT (Figure 26), and these same conditions for an 
enzyme activity assay (Figure 27). In cell invasion, 40-75% inhibition is exhibited in 
response to these inhibitors. Our enzyme activity assay, however, does not exhibit the 
same effect from our inhibitors. Both Rac2 alone and Rac2 + PLD2 transfectants when 
used to determine lipase activity were consistently resistant to inhibition by these 
compounds, except for FIPI, which did slightly negatively impact lipase activity of these 
2 transfectants. The capability of the compounds to inhibit Rac2 WT and co-transfected 
Rac2 WT + PLD2 WT in cell invasion and not in enzyme activity suggests Api, 5WO, 
809 and APV operate independent of PLD. This PLD independent mechanism is having 
off-target effects on other proteins and pathways, allowing for inhibition in cell invasion 
but not on endogenous lipase activity, affecting functions not specific to PLD.  
 
G. CRIB-Mediated Cell Invasion and PLD Enzyme Activity 
 The PH domain of PLD2 is from amino acid 210-313. CRIB1 is located entirely 
within the PH domain of PLD2 (I255-HGV280), while CRIB2 extends slightly beyond 
the PH domain (I306-H323). Because CRIB is the domain on PLD2 where Rac2 binds, 
partial deletions of this domain were made to observe the effect it has on Rac2 binding to 
PLD2. Overexpression of these mutants were shown in Western Blot (Figure 28a) and 
assayed in cell invasion (Figure 28b). ∆CRIB1 has an insignificant effect on cell invasion 






Figure 26:  
 PLD2 WT is used as a positive control. Cell invasion with overexpressed Rac2 WT are 
inhibited by our compounds of interest. 809, APV and FIPI inhibit cell invasion by 40% 
in the Rac2 WT sample, Api and 5WO by 65%. With our co-transfected PLD2 WT + 









Figure 27:   
The mock sample with DMSO is used as a negative control and PLD2 WT is once again 
the positive control. The effect of Rac2 WT on endogenous PLD lipase activity (green 
bars) is inhibited slightly by 5WO and APV at 15%, FIPI at 50%, and no inhibition is 
observed with Api and 809. Co-transfected Rac2 WT + PLD2 WT were only inhibited by 











Figure 28:   
Part A is a Western Blot of the overexpressed ∆CRIB mutants (PLD1 WT and KR data 
not shown). Part B illustrates the negative effects on cell invasion by overexpressed 
∆CRIB mutants when compared to the PLD2 WT positive control. Although above the 
EGF control, the ∆CRIB mutants are within a PLD2 construct, only by enhancing cell 






compensate for each other. When ∆CRIB1 is overexpressed, Rac2 may still partially bind 
to PLD2 via the CRIB2 domain, and vice versa. This compensatory effect was reaffirmed 
by PLD enzyme activity (Figure 29). With ∆CRIB1 and ∆CRIB2 overexpressed, PLD 
activity is lower than overexpressed PLD2 WT. This effect is consistent with the PLD 
lipase activity when Rac2 was transfected into MTLn3 cells. The specificity of Rac2 
binding to the CRIB domain is inconsequential in this cell line, as neither deletion was 
able to completely deter Rac2 binding to PLD2.   
 
H. Effect of Inhibitors on CRIB-Mediated Cell Invasion and PLD Enzyme Activity  
 The overexpressed CRIB mutants were then exposed to the 5 inhibitors in a cell 
invasion assay (Figure 30a). Api and FIPI inhibit cell invasion on both CRIB mutants by 
55% and 70%, respectively. However, 5WO, 809 and APV inhibit ∆CRIB1 by ~30%, 
with only 5WO having the same effect on ∆CRIB2. As mentioned earlier, ∆CRIB1 and 
∆CRIB2 are compensated by the half of the CRIB domain still intact on the PLD2 
molecule. Because Rac2 has no preference for either half of the amino acid residues 
located within the CRIB domain, the cell invasion results with inhibitors share 
resemblance in their response to our PLD2 WT controls. In addition to cell invasion, we 
performed an enzyme activity assay with inhibitors with ∆CRIB2 (Figure 30b).  
AIM 4: To Investigate the Effect of Kinase Phosphorylation of PLD2 on PLD2-
Mediated Cell Invasion and Lipase Activity.  
 
A. Roadmap of Proteins and Protein Interactions 
 
The fourth and final aim was to investigate the effect of kinases specific to PLD2 









        
 
 
Figure 29:   
The enzymatic activity of PLD2 when the CRIB mutants are overexpressed is consistent 
with the cell invasion data. ∆CRIB1 and ∆CRIB2 are both above the negative (mock) 




          
Figure 30:  
 In Part A, the effect of the inhibitors on cell invasion with overexpressed ∆CRIB mutants 
is shown. ∆CRIB1 elicits a stronger response from the inhibitors than ∆CRIB2. Part B is 
the effect of the inhibitors on ∆CRIB2 lipase activity. 5WO and FIPI inhibited enzyme 





Figure 31:   
The final aim of this study is the effect of kinase phosphorylation of PLD2 on PLD2-















eliminating specific kinase phosphorylation sites on PLD2. Each kinase has a specific site 






-Src), whereby all 3 kinases are regulators of 






 tyrosyl phosphorylation sites located 
on PLD2, we defined their effect on cell invasion and enzymatic activity, as well as the 
effect of our 5 inhibitors on Y296F.  
 
 
B. Overexpressing Plasmid DNA for Cell Invasion in Matrigels  
 We overexpressed the YF mutants in a cell invasion assay to observe their effects 
on cell invasion once kinase phosphorylation on PLD2 is lost (Figure 32). We observed 
large decreases in cell invasion from the overexpressed Y415F and Y511F mutants, and 
enhancement of cell invasion with the overexpressed Y296F mutant. Until this point, 
none of the plasmids when transfected alone enhanced cell invasion beyond PLD2 WT. 
Because the Y
296 
site is incapable of being phosphorylated by EGF-R, this increase in cell 
invasion implicates the EGF-R kinase phosphorylation at the Y
296 
site of PLD2 as 
inhibitory to cell invasion. The dominant negative effects of Y415F and Y511F are due to 
inactive molecular function, resulting in an antagonistic effect on PLD2.  
 
C. Effect of Inhibitors on Y296F-Mediated Cell Invasion and PLD Enzyme Activity 
 Due to the emergence of Y296F as a stronger enhancer of cell invasion than 
PLD2 WT, we assayed the effect of our 5 inhibitors in cell invasion (Figure 33) and 
lipase activity (Figure 34). These results indicate that the significantly higher lipase 




Figure 32:   
This cell invasion assay illustrates the effect of the overexpressed PLD2 YF mutants on 
cell invasion. The Y296F mutant enhances cell invasion above the PLD2 WT positive 
control by 25%. Our Y415F and Y511F mutants decrease cell invasion by 75% and 50%, 
respectively. This data indicates that when these tyrosine sites on PLD2 are 














Figure 33:   
PLD2 WT is used a positive control. The enhancing effect in cell invasion by Y296F was 
able to be inhibited significantly. Api and 809 decreased cell invasion by 65%, 5WO by 







Figure 34:   
This PLD enzymatic assay illustrates the 3-fold increase of catalytic activity that Y296F 
has over the PLD2 WT positive control, consistent with its enhancing effect on cell 
invasion. Our 5 compounds strongly inhibited catalytic activity, Api and 5WO by 50%, 





1. PLD2 WT promotes cell invasion. PLD1 WT increases invasion above the EGF 
control, however, it is below the PLD2 WT positive control, therefore not as potent an 
enhancer of cell invasion. Both PLD KR mutants significantly decrease cell invasion. 
2. Silencing PLD1 was unsuccessful; the silencing of PLD2 resulted in decreased protein 
expression and lipase activity resulting in an 85% decrease of cell invasion when 
compared to the EGF and negative siRNA control. With no EGF stimulation, siPLD2 
decreased cell invasion by 50% compared to the negative Mock control.  
3. Our 5 potential inhibitors targeted and inhibited PLD2 cell invasion and lipase activity 
significantly (~50% decrease) at subnanomolar concentrations; inhibition of PLD1 was 
not achieved.  
4. Grb2 WT had a positive effect on cell invasion compared to the EGF control, but was 
not an enhancer of cell invasion when compared to PLD2 WT. The SH2 domain deficient 
Grb2 R86K mutant had no effect on cell invasion compared to the EGF control and was 
significantly below that of the positive control. SH3 domain deficient Grb2 p49/206L 
was strongly inhibitory on cell invasion compared to both controls. When these 3 
plasmids were co-transfected with PLD2 WT: Grb2 WT + PLD2 WT was an enhancer of 
cell invasion, Grb2 R86K + PLD2 WT performed the same as PLD2 WT only and Grb2 
p49/206L + PLD2 WT was largely inhibitory when compared to the positive control.  
5. Overexpression of PLD2 mutants Y169F, Y179F and Y511F all significantly 
decreased cell invasion between 60-90%.  
6. Silencing Grb2 decreased cell invasion by 75%, although the effects were less than that 
of siPLD2. siGrb2 + siPLD2 co-silencing almost completely abrogated cell invasion.  
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7. Silencing PLD2 has no effect on Grb2 protein expression.  
8. The 5 compounds successfully inhibited Grb2 WT and co-transfected Grb2 WT + 
PLD2 WT in cell invasion. Api, 5WO, 809 and APV decreased cell invasion by 60%. 
FIPI emerged as the strongest inhibitor in the co-transfected sample, decreasing cell 
invasion by 70% 
9. FIPI was capable of inhibiting the lipase activity of PLD2 WT by up to 90%. 
10. Rac2 WT has a neutral to negative effect on cell invasion. Rac2 N17 increases cell 
invasion above that of the EGF control but less so than the PLD2 WT positive control, 
indicating a positive response when Rac2 is constitutively GDP-bound.  
11. Rac2 has a more pronounced negative effect when interacting with PLD2. When 
Rac2 WT was simultaneously transfected with PLD2 WT cell invasion largely decreased, 
when sequentially transfected before PLD2 WT, cell invasion was again decreased. 
When the sequential transfection was inversed, cell invasion was actually enhanced.  
12. The results of cell invasion of Rac2 + PLD2 are consistent with lipase activity when 
co-transfected, recombinant PLD2 enzymatic activity is decreased to that of endogenous 
levels. 
13. Silencing Rac2 resulted in a 30% decrease in cell invasion, indicating a potential role 
in cell invasion independent of PLD2. Overexpressing PLD2 WT was able to rescue 
siRac2 and increase cell invasion.  
14. With no EGF stimulation, siRac2 + PLD2 WT exhibited a 70% decrease in cell 
invasion, while stimulation with EGF yielded a 40% increase in cell invasion. This 
implicates an EGF-mediated interaction between the two proteins.  
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15. Immunoprecipitation revealed Rac2 protein expression to be suppressed when PLD2 
WT is overexpressed.  
16. Rac2 WT overexpression in cell invasion was inhibited by the compounds: 809, APV 
and FIPI by 40%, Api and 5WO by 65%. Rac2 WT + PLD2 WT were inhibited evenly 
by 50% when any of the 5 compounds were present. 
17.  The effect of Rac2 WT on endogenous PLD was only partially inhibited by the 
compounds: 5WO and APV by 15%, FIPI at 50% and no inhibition with Api or 809. 
Rac2 WT + PLD2 WT was only inhibited by FIPI (40%).  
18. Compared to the positive control, ∆CRIB1 had a negative effect on cell invasion, 
while ∆CRIB2 was slightly more neutral.  
19. ∆CRIB1 and ∆CRIB2 decreased endogenous levels of PLD activity when 
overexpressed, consistent with cell invasion results.  
20. In regards to cell invasion and lipase activity, the specificity of Rac2 binding to the 
CRIB domain is inconsequential in this cell line, as neither deletion was able to 
completely deter Rac2 binding to PLD2. 
21. ∆CRIB1 and ∆CRIB2 were inhibited similarly by the compounds in cell invasion: 
∆CRIB1 and  ∆CRIB2 with Api by 55% and FIPI by 70%, 5WO, 809, and APV inhibited 
∆CRIB1 by 30%, while only 5WO had the same effect on ∆CRIB2. In PLD enzyme 
activity: 5WO and FIPI inhibited lipase activity by 50%, with no effect from Api or APV 
and a spike in activity with 809.  
22. Y415F and Y511F exhibited large negative effects on cell invasion, while Y296F 
emerged as the sole overexpressed plasmid to enhance cell invasion.  
23. The lipase activity of Y296F yielded a 3-fold increase over PLD2 WT 
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24. Inhibition of Y296F by the compounds in both cell invasion and lipase activity were 
very similar in effect and magnitude to PLD2 WT.  In cell invasion, Api and 809 
decreased cell invasion by 65%, 5WO by 75% and APV and FIPI by 70%. The 
compounds inhibited lipase activity effectively: Api and 5WO by 50%, FIPI by 60% and 





















PLD2-mediated cell invasion 
 The results confirmed that PLD2 mediates cell invasion in the MTLn3 cell line 
when stimulated by EGF (Figure 35). The consistent enhancement of cell invasion when 
PLD2 was the sole transfectant was 40% above the EGF control on average. 
Additionally, the silencing of PLD2 decreased cell invasion between 70-85%.  
 
 
Protein-Protein Interaction with Grb2 
 
 Grb2 WT does not enhance cell invasion nor increase endogenous PLD activity. 
However, the silencing of Grb2 resulted in a 75% decrease in cell invasion and the co-
silencing of Grb2 + PLD2 almost completely abrogates it. When Grb2 is co-transfected 
with PLD2, cell invasion and lipase activity were slightly enhanced, indicating a role for 
Grb2 as a complementary partner in PLD2-mediated cell invasion. The PLD2 YF and 
Grb2 mutants that eliminate the interaction of PLD2 with Grb2 have significantly 
negative effects on cell invasion. When compared to PLD2 WT, Grb2 R86K was 30% 
decreased, Grb2 p49/206L and Y511F decreased 60%, Y169F was decreased 70% and 
Y179F was decreased 80%. Grb2 is incapable of interacting with PLD2 when the R86K 
mutant is overexpressed due to the loss of the SH2 domain 
21
. The SH3 domain-
deficiency of the Grb2 p49/206L double mutant when overexpressed results in the loss of 







bind to Grb2, modulate activity and regulate tyrosine 
phosphorylation, respectively 
21
. Both of these tyrosine residues are necessary for the 
recruitment of Sos. MTLn3 cells are less invasive when Grb2 cannot bind to PLD2, but  
 69 
         
   
Figure 35:   
The interaction between Grb2 and PLD2 through specific tyrosine residues on PLD2 
target the SH2 domain of Grb2, recruiting Sos to the SH3 domain of Grb2 in a trimeric 
complex. The PLD2 tyrosine specific kinases act upon their respective sites. The Y
511
 site 
is involved in both functions, however its ability to bind to Grb2 is more limited, as its 
main function is as a kinase phosphorylation site. GTP-bound Rac2 WT binds to PLD2 
on the CRIB domain, negatively affecting catalytic activity. When sufficient amounts of 
PA are produced within the cell, S6K is phosphorylated to mediate actin polymerization 
at the leading edge of the cell, resulting in invasion 
91
.   
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even less so when PLD2 cannot interact with the Grb2/Sos complex to promote GTP 
loading of Ras. Ras effectors are no longer activated, nor are the Ras/MAPK pathways 
downstream, resulting in an inhibitory effect on cell invasion. Ho et. al have shown that 
inhibition of cell invasion and migration can be achieved by suppressing the MAPK 
pathway through inhibition of Grb2 (among others such as Ras, Rho and ERK)
92
, which 
indicates the PLD2/Grb2 interaction as a prominent target of inhibition. The interaction 
between PLD2 and Grb2 is a crucial cellular signaling process within PLD2-mediated 
pathways and although not a synergistic effect between the two, the presence of both 
proteins is essential in PLD2-mediated cell invasion.  
  
Protein-Protein Interaction with Rac2 
 
 Rac2 WT has a neutral to negative effect on cell invasion when transfected alone, 
conversely, the mutant GDP-bound Rac2 N17 is constitutively inactive, resulting in an 
increase in cell invasion. These negative effects become more pronounced with 
concomitant amounts of Rac2 WT co-transfected with PLD2 WT. When recombinant 
proteins are co-transfected into MTLn3 cells, Rac2 inhibits both endogenous and 
overexpressed PLD2 enzymatic activity. Parker et. al have shown that Rac2 is 
downregulated in ovarian cancer 
93
, in agreement with our results that Rac2 may possess 
antagonistic properties in cancer progression. The negative effect of Rac2 on PLD2 was 
only overcome when PLD2 WT was sequentially transfected before Rac2 WT, allowing a 
longer time period in which PLD2 can be expressed prior to cell invasion. A schematic 
from our lab has proposed competition with PIP2 as the main cause of negative 









Figure 36:   
In part A, at basal levels or early stages of chemoattractant exposure, PLD2 binds to PIP2 
freely and PLD enzymatic activity is unperturbed. When chemoattractant is present in 
higher amounts, or exposure time is lengthened, the amount of GTP-bound Rac2 present 
within the cell increases. Competition with PIP2 available on the cell membrane, as well 
as the binding of Rac2 to the CRIB domain located on PLD2’s PH domain, negatively 




in the presence of EGF. When siRac2 + overexpressed PLD2 WT were co-transfected, 
the negative effect of siRac2 in cell invasion was rescued in the presence of EGF, which 
resulted in an overall increase in cell invasion when compared to the mock sample. When 
EGF was not present for this condition, a 70% decrease in cell invasion was observed, 
indicating that Rac2 has an EGF-mediated effect on PLD2. Therefore, in basal stages or 
limited exposure to chemoattractant, PLD2 freely binds to PIP2 without interference from 
Rac2. When EGF increases in concentration, the inverse effect occurs, in which GTP-
bound Rac2 competes with PIP2 binding on the cell membrane. PLD2, increasingly 
unable to bind PIP2, is additionally bound more frequently by Rac2 on its PH domain. 
This dynamic, in turn, results in a decrease of cellular PA production, decreasing lipase 
activity and cell invasion.  
 The protein-protein interaction of Rac2 and PLD2 occurs on the CRIB domain of 
PLD2 (Figure 37), which was studied through the use of the ∆CRIB1 and ∆CRIB2 
mutants. When the ∆CRIB mutants were overexpressed, they were unable to enhance cell 
invasion. The lipase activity of PLD2 was decreased, as Rac2 was still able to bind to 
PLD2. These results indicated that the specificity of Rac2 binding to the CRIB domain is 
inconsequential in this cell line, as neither deletion was able to completely deter Rac2 
from binding to PLD2.  
 
 
The effect of kinase phosphorylation on PLD2 
 
 Three sites on PLD2 regulated by kinase phosphorylation were examined through 
the use of the YF mutants which are incapable of being phosphorylated by certain 








Figure 37:   
CRIB1 (I255-HGV280) and CRIB2 (I306-H323) were deleted in our ∆CRIB mutants to 
counteract the negative effect of Rac2 on PLD2 catalytic activity. These deletions were 
ineffective in the MTLn3 cell line due to the non-specific nature of Rac2 binding on the 








respectively, while Y296F enhanced cell invasion by 25%. Additionally, Y296F 
increased the lipase activity of PLD2 3-fold over PLD2 WT and was the only plasmid 
transfected solely that was capable of enhancing both cell invasion and lipase activity. 




 are activatory sites on PLD2, while Y
296
 is 




: Jak3) and 
(Y
511
: Src) were examined in greater detail by our lab (Figure 38). Figure 38a depicts the 
decrease of PLD2 lipase activity when Y415F and Y511F are overexpressed. Our second 
figure, 38b, is the result of incubating our Y296F plasmid with the kinases EGF-R, Jak3 
and Src to determine their effect on Y296F lipase activity. Because the Y296 site is no 
longer available for phosphorylation, EGF-R has no effect, while Jak3 and Src increase 
lipase activity by 40% and 45%, respectively. The kinases Jak3 and Src are activators of 
PLD2, which compensate for the inhibitory effect of EGF-R. Henkels et. al have shown 
the Y
296 
site as inhibitory in MCF-7 cells, a low-invasive breast cancer cell line that 
exhibits little lipase activity 
37
. MTLn3 cells have medium to low lipase activity 
37
 and 
both are estrogen receptor positive. This places MTLn3 cells as an intermediate between 
high lipase and low lipase expressing breast cancers, indicating catalytic activity in these 
cells as one factor, while reaffirming the importance of the protein-protein interactions 
and their mitogenic signaling effects in the PLD pathway.  
 The capability of PLD2 overexpression to increase cell growth and induce cell 
transformation has been well characterized by the lab of David Foster 
94,95
 and Henkels 
et.al have shown that when PLD2 lipase activity is low due to PLD2 phosphorylation 
deficiency, cellular proliferation is decreased 
66
, both results in accordance concerning 
the consequence of PLD2 and its lipase activity. The compensatory effects of the Jak3  
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Figure 38:   
Both figures utilize the MTLn3 cell line. Part A depicts the decrease in PLD enzyme 
activity when Y415F and Y511F are overexpressed, and the enhancing effect when 
Y296F is overexpressed. Part B depicts the effect of Y296F on enzyme activity, which is 
increased by Jak3 and Src kinases, while EGF-R has no effect, as the Y
296 
site is no 




and Src kinases are utterly crucial for PLD2-mediated cell invasion; therefore, the 
knockdown of these two specific kinases would greatly decrease the invasive capabilities 
of MTLn3 cells undergoing metastasis.  
 
The inhibitory effect of our 5 potential inhibitors 
 The 5 potential inhibitors used in this study were Apigenin, 5WO, 809, APV and 
FIPI. While Apigenin and FIPI have been characterized by others, 5WO, 809 and APV 
are still relatively uncharacterized. Frohman’s lab has shown that FIPI specifically targets 
PLD 
84
, with inhibitory results on PLD2 activity similar to those found in this study. The 
other 4 compounds, Api, 5WO, 809 and APV have been proposed to also have an affinity 
for targeting PLD. All 5 compounds were able to inhibit PLD2 WT cell invasion and 
lipase activity by at least 50%. However, when the Grb2/PLD2 and Rac2/PLD2 protein-
protein interactions were elucidated, FIPI emerged as the strongest and most consistent 
inhibitor in both cell invasion and lipase activity. Apigenin was the least effective, while 
5WO, 809 and APV all had middling effects on inhibiting cell invasion and lipase 
activity, indicating these 4 compounds operate independent of PLD. When PLD2 WT + 
Grb2 WT were co-transfected, FIPI inhibited cell invasion and lipase activity by 70%. 
We also observed up to 90% inhibition on overexpressed PLD2 WT lipase activity when 
FIPI was present. When looking at Rac2, cell invasion was consistently inhibited across 
the board; however, the effect of Rac2 on endogenous PLD was only significantly 
inhibited by FIPI (50%), as well as the lipase activity of co-transfected Rac2 WT + PLD2 
WT (40%). FIPI was also capable of inhibiting the effect of CRIB2 on lipase activity 






 and natural products (such as Honokiol), a compound that suppresses tumor 
growth in mice and has been shown to suppress PLD activity in human cancer cells 
98
. 
These compounds either sequester the requisite PLD cofactor PIP2, work indirectly to 
inhibit PLD activity, or have effects independent from the PLD signaling pathway. 5WO, 
809 and APV are compounds operating through undetermined mechanisms, their 
inhibition on PLD shown in this study are indirect effects not specific to PLD. The results 
show inhibition of PLD2-mediated cell invasion and lipase activity, but inadequate 
inhibition on Rac2 and Grb2’s effects on endogenous lipase activity. This confirms 5WO, 
809 and APV are only indirectly inhibiting PLD. The decrease in inhibition when 
protein-protein interactions are involved might be due to the fact that the compounds 
effect downstream signaling molecules, or 5WO, 809 and APV bind to the same sites on 
PLD where PLD-associated proteins like Grb2 and Rac2 bind. Apigenin has many known 
mechanisms through which it inhibits, and has shown promise in inhibiting tumor cell 
invasion and metastases through regulation of protease production 
85
, the results from this 
study; however, show no specific effect for PLD. Again, the protein-protein interactions 
revealed in this study show the effect of Api on PLD2-mediated cell invasion and lipase 
activity are indirect, due to Api’s inhibitory effects on other proteins and signaling 
pathways.   
Api, 5WO, 809 and APV all provided inhibitory effects, although independent of 
PLD, indicating promising therapeutic utilization on other proteins and signaling 
pathways. Based on the results of this study, it is evident that the inhibition of PA by FIPI 
84
 is the most prevalent way to target and decrease PLD-mediated cell invasion and lipase 
activity. The potent and specific effects of FIPI have proved to be the most effective at 
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decreasing PLD-mediated cell invasion. MTLn3, as an optimal model of breast cancer, 
necessitates PLD2-mediation for efficient intravasation, in which FIPI can interrupt to 
deter metastatic progression.     
 
Therapeutic Approach 
 We propose here, that a therapeutical approach could be made possible that would 
inhibit the crucial step of PLD2-mediated cell invasion during metastasis in MTLn3 cells. 
The ability of FIPI to inhibit PLD2-mediated cell invasion and lipase activity is the 
reason for its inclusion as one part of our therapeutic approach. The other part of this 
approach is focused upon PLD2 regulation by kinase phosphorylation, in which we know 
that the kinases Jak3 and Src can phosphorylate PLD2 and increase its lipase activity. 
Protein-protein interactions with PLD2 indicate that in the presence of EGF, Rac2 is 
inherently acting against cell invasion through a negative catalytic interaction, while 
Grb2 serves as a partner for PLD2 to activate cellular functions congruent with cell 
invasion. PLD lipase activity can be increased up to 3-fold above normal when EGF-R 
kinase phosphorylation is lost, indicating a second protein that can negatively interact 
with PLD2. As the EGF-R kinase negatively regulates PLD2, knocking down the 
activator kinases Jak3 and Src, which compensate for PLD2 activity, should provide a 
lower threshold in which PLD2 can mediate cell invasion. This knockdown of the Jak3 
and Src kinases, in combination with utilization of the small molecule inhibitor FIPI to 
inhibit PA production, may result in the inhibition of PLD2-mediated cell invasion to 
near basal levels in spite of stimulation by EGF. The result of lower PLD2 lipase activity, 
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in conjunction with decreased cellular PA production, should protect against the 























VIII. Significance of Study 
 Cell invasion is a crucial component of angiogenesis and metastasis and often 
targeted in cancer therapy. The prowess of PLD to mediate cell invasion is well 
characterized, and specific interactions with other proteins involved in cancer progression 
were further examined here. The effects on cell signaling by Grb2 and Rac2 in MTLn3 
cells give us further insight into the mechanisms regulating this adenocarcinoma, 
including one of the foremost examples of the Rac2/PLD2 interaction in cancer. Our 
therapeutical approach presents a strong opportunity to inhibit tumor progression not only 
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